Dr Reddys Laboratories Ltd (RDY) stock analysis
Close on Nov 11, 2026Market cap $12.39BP/E 27.1Yield 0.57%
StockData Score
Prices as of Nov 11, 2026How the score works
Weak7 of 30 checks passed
Dr Reddys Laboratories passes 7 of the 30 checks behind our score; 17 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 1/6
- Past performance
- 2/6
- Financial health
- 4/6
- Dividend
- 0/6
What stands out
Low debt
Debt is 20.5% of shareholders' equity, under the 40% we consider low.
Revenue growing 10%+ a year
Revenue grew 11.0% a year over the last three fiscal years.
Interest well covered
Operating income covers interest expense 13.5 times.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 73.4% of total debt.
What to watch
Return on capital under 10%
Return on invested capital was 9.7%, below the 10% that usually covers the cost of capital.
EPS growing under 10% a year
Diluted EPS grew -1.7% a year over the last three fiscal years.
Growing slower than the industry
Revenue grew 3.2% over the last twelve months; the Drugs median is 8.0%.
Gross margin slipping
Gross margin was 52.8% over the last twelve months, against 58.5% a year earlier.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth1/6
Revenue growing 10%+ a year
Revenue grew 11.0% a year over the last three fiscal years.
EPS growing under 10% a year
Diluted EPS grew -1.7% a year over the last three fiscal years.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew 3.2% over the last twelve months; the Drugs median is 8.0%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin slipping
Gross margin was 52.8% over the last twelve months, against 58.5% a year earlier.
Past performance2/6
Return on equity
Needs positive equity and five years of results.
Return on capital under 10%
Return on invested capital was 9.7%, below the 10% that usually covers the cost of capital.
Return on equity above the industry
Dr Reddys Laboratories's return on equity of 12.1% is above the Drugs median of -58.9%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin below its 5-year average
Net margin was 12.8% over the last twelve months, against a 5-year average of 17.1%.
Net margin above the industry
Dr Reddys Laboratories's net margin of 12.8% is above the Drugs median of -53.0%.
Financial health4/6
Low debt
Debt is 20.5% of shareholders' equity, under the 40% we consider low.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 73.4% of total debt.
Interest well covered
Operating income covers interest expense 13.5 times.
Short-term assets cover short-term debts
Current assets are 1.80 times current liabilities.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
Dr Reddys Laboratories has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Dr Reddys Laboratories. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $40.38M
- Value traded per 1% price move
- $33.27M
Downside
Medium risk
- Typical loss in a bad month
- 18.8%
- Volatility (annualized)
- 27%
- Sharpe ratio, 1 year
- 0.20
- Beta to the S&P 500 (5Y)
- 0.35
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2016 to 2026
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +3.2% | +11.0% | +12.1% | +8.1% | |
| Gross profit | -6.9% | +8.4% | +11.5% | +6.7% | |
| Operating income | -29.6% | -4.0% | +15.8% | +5.5% | |
| Net income | -24.2% | -1.7% | – | +7.9% | |
| EPS, diluted | -24.1% | -1.7% | +19.9% | +8.2% | |
| Free cash flow | +76.6% | -11.1% | +5.2% | +1.4% | |
| Dividend per share | 0.0% | -35.6% | +9.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 12.1% | |
| Return on assets | – | – | 8.0% | |
| Current ratio | 1.18 | 1.78 | 1.80 | |
| Debt to equity | – | – | 0.21 | |
| Net debt to EBITDA | 1.83× | 0.42× | 0.87× | |
| Interest coverage | 17.3× | 25.0× | 13.5× | |
| Inventory turnover | – | 2.2× | 2.1× | |
| Capex to revenue | 8.7% | 5.1% | 6.9% | |
| Diluted shares | 835M | 832M | 833M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Dr Reddys Laboratories generated ₹235.60B from operations and spent ₹122.31B on capital expenditure, dividends and share buybacks. 76% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 12.8% | 0.63× | 1.51× | 12.1% |
| FY2025 | 17.4% | 0.74× | 1.43× | 18.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
- ProfitableNet income above zero₹42.85B
- Cash generatingOperating cash flow above zero₹56.76B
- Return on assets improvedROA up on the prior year14.6% → 8.7%
- Earnings backed by cashOperating cash flow above net income₹56.76B vs ₹42.85B
- Less leverageLong-term debt to assets fell1.6% → 2.1%
- Better liquidityCurrent ratio rose1.92 → 1.80
- No dilutionShare count did not rise834M → 833M
- Gross margin improvedGross margin up on the prior year58.50% → 52.77%
- More efficientAsset turnover rose0.84 → 0.68
See a number that looks wrong?